Nureca Ltd
NURECANureca Ltd
NURECA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 532.03 | 1.57 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Nureca Ltd is engaged in the marketing of home healthcare & wellness products
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.02 | 216.27 | 61.99 | 99.49 | 216.27 | 263.25 | 118.43 | 102.44 | 104.60 | |||||||||
Raw Materials | 0.02 | 151.91 | 50.16 | 67.49 | 120.01 | 159.55 | 44.76 | 56.23 | 100.64 | |||||||||
| Power & Fuel Cost | 0.00 | 0.02 | 0.04 | 0.01 | 0.16 | 0.20 | 0.13 | |||||||||||
| Employee Cost | 0.00 | 0.89 | 3.16 | 4.58 | 9.91 | 16.06 | 12.20 | |||||||||||
| Selling & Administrative Expenses | 0.00 | 11.12 | 19.66 | 44.81 | 51.71 | 30.34 | 24.91 | |||||||||||
| Operating & Other expenses | 0.00 | -9.35 | -0.61 | -17.50 | -21.29 | 34.97 | 8.67 | |||||||||||
EBITDA | 0.00 | 64.36 | 9.15 | 9.75 | 64.36 | 63.21 | -7.90 | 0.30 | 3.96 | |||||||||
| Depreciation/Amortization | 0.00 | 0.42 | 0.06 | 0.37 | 0.42 | 1.48 | 2.39 | 2.36 | 2.44 | |||||||||
| PBIT | 0.00 | 63.94 | 9.09 | 9.38 | 63.94 | 61.73 | -10.29 | -2.06 | 1.52 | |||||||||
| Interest & Other Items | 0.00 | 1.60 | 0.24 | 0.77 | 1.60 | 0.74 | 0.45 | 0.49 | 0.52 | |||||||||
| PBT | 0.00 | 62.34 | 8.85 | 8.61 | 62.34 | 60.99 | -10.74 | -2.55 | 1.00 | |||||||||
| Taxes & Other Items | 0.00 | 15.96 | 2.61 | 2.22 | 15.96 | 16.02 | -2.49 | -0.75 | 0.43 | |||||||||
| Net Income | 0.00 | 46.38 | 6.24 | 6.39 | 46.38 | 44.97 | -8.25 | -1.80 | 0.57 | |||||||||
| EPS | 0.00 | 62.04 | 891.43 | 912.86 | 92.11 | 44.97 | -8.25 | -1.80 | 0.57 | |||||||||
| DPS | 0.00 | — | 0.00 | 0.00 | 2.00 | 3.00 | 0.00 | — | 0.00 | |||||||||
| Payout ratio | — | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nureca Ltd | -168.48 | 1.57 | — |
| Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
| Cipla Ltd | 31.71 | 4.88 | 0.80% |
| Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare NURECA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 24, 2022
Dividend/Share
₹3.00
Ex DateEx Date
Feb 24, 2022
Cash Dividend
Ex DateEx DateSep 21, 2021
Dividend/Share
₹2.00
Ex DateEx Date
Sep 21, 2021
Nureca reports consolidated net profit of Rs 1.66 crore in the June 2024 quarter
Net profit of Nureca reported to Rs 1.66 crore in the quarter ended June 2024 as against net loss of Rs 0.71 crore during the previous quarter ended June 2023. Sales declined 4.52% to Rs 20.27 crore in the quarter ended June 2024 as against Rs 21.23 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales20.2721.23 -5 OPM %-11.64-13.66 - PBDT3.28-0.35 LP PBT2.62-0.93 LP NP1.66-0.71 LP Powered by Capital Market - Live
Nureca will hold a meeting of the Board of Directors of the Company on 5 August 2024.Powered by Capital Market - Live
Nureca Standalone December 2022 Net Sales at Rs 27.84 crore, down 42.1% Y-o-Y
Nureca Consolidated December 2022 Net Sales at Rs 27.79 crore, down 42.2% Y-o-Y
Nureca consolidated net profit declines 93.66% in the December 2022 quarter
Sensex shed 236 pts, Nifty at 18,028; Nureca zooms 20%, Coforge and Paytm rise 4% each
Nureca shares rebound 25% from day’s low amid heavy volumes, up 17%
Agri-Tech (India) Ltd leads gainers in ‘B’ group
Bharat Immunological & Biological Corporation Ltd leads gainers in ‘B’ group
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.57%, vs industry avg of 9.21%
Constant Market Share
Over the last 5 years, market share stayed at 0.03%